胰腺切除同期行远端脾肾分流与肠系膜腔静脉分流的长期结果
本研究基于前瞻性数据库,纳入34例在胰腺切除同期或之后接受肠系膜腔静脉分流或远端脾肾分流的患者,其中25例在胰十二指肠切除术时完成。中位手术时间9小时,中位估计出血量950 mL,4例发生需干预的并发症(Clavien-Dindo≥III级),无90天死亡。腺癌患者中位随访19个月时中位总生存31个月,除1例远端脾肾分流外所有分流在末次随访时通畅。
要点
- 肿瘤包绕肠系膜上动脉时,分流有助于安全分离门脉区和肿瘤
- 34例中无90天死亡,4例需干预并发症
- 除1例远端脾肾分流外,其余分流末次随访均通畅
核心结论
- 胰腺切除同期行肠系膜腔静脉分流或远端脾肾分流,可使需复杂胰腺切除的患者获得安全完整的肿瘤切除,其中不少患者原本会被视为不可手术。
研究设计与样本
- 从前瞻性数据库识别所有行胰腺切除并接受肠系膜腔静脉分流或远端脾肾分流的患者,回顾人口学、围术期治疗和结局。
- 共34例:25例在胰十二指肠切除术时、6例在全胰腺切除时、3例在此前胰腺切除后行分流。
- 分流类型:15例肠系膜腔静脉分流、16例远端脾肾分流、2例肠系膜腔静脉与远端脾肾联合分流、1例远端脾肾上腺静脉分流。
- 肠系膜腔静脉分流组包括11例临时和6例永久(其中3例延迟)分流。
主要发现
- 中位手术时间9小时(范围6.5-13),中位估计出血量950 mL(范围200-5,000),中位住院时间11天(范围7-35)。
- 4例发生需干预的并发症(Clavien-Dindo≥III级),无90天死亡。
- 腺癌患者中位随访19个月时中位总生存31个月。
- 除1例远端脾肾分流外,所有分流在末次随访时通畅。
临床怎么用
- 对胰腺肿瘤包绕肠系膜上静脉-门静脉-脾静脉汇合且紧贴肠系膜上动脉后外侧壁者,可考虑切除同期行肠系膜腔静脉分流(联合或不联合远端脾肾分流),以利于门脉区解剖和肿瘤与肠系膜上动脉分离。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When pancreatic neoplasms occlude or encase the superior mesenteric-portal-splenic vein confluence with abutment of the posterior lateral wall of the superior mesenteric artery, a mesocaval shunt with or without a distal splenorenal shunt allows for safe dissection of the porta hepatis and separation of the pancreatic tumor from the superior mesenteric artery. Herein we report long-term results of the largest known series of portosystemic shunts performed at the time of pancreatectomy. METHODS: All patients who underwent pancreatic resection with a mesocaval shunt or distal splenorenal shunt were identified from our prospective database. Demographics, perioperative treatment, and outcomes were reviewed. RESULTS: A total of 34 patients underwent mesocaval shunt or distal splenorenal shunt, including 25 at the time of pancreatoduodenectomy, 6 during total pancreatectomy, and 3 after prior pancreatectomy. There were 15 mesocaval shunts, 16 distal splenorenal shunts, 2 combined mesocaval/distal splenorenal shunts, and 1 distal splenoadrenal vein shunt. The mesocaval group included 11 temporary and 6 permanent (3 delayed) shunts. Median operative time was 9 hours (range 6.5-13), median estimated blood loss was 950 mL (range 200-5,000), and median duration of hospital stay was 11 days (range 7-35). Four patients experienced complications that required intervention (Clavien-Dindo grade ≥III), but there were no 90-day mortalities. For patients with adenocarcinoma, median overall survival was 31 months at a median follow-up of 19 months. All but 1 shunt (distal splenorenal) were patent at last follow-up. CONCLUSION: Mesenteric venous shunting facilitates a safe and complete tumor resection in patients who require a complex pancreatectomy, many of whom would otherwise be deemed inoperable.
引用
- Chavez MI, Tsai S, Clarke CN, et al. Distal splenorenal and mesocaval shunting at the time of pancreatectomy. Surgery. 2018. PMID: 30471779. doi:10.1016/j.surg.2018.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。